Two Treatments for Persistent Atrial Fibrillation with Heart Failure
Compares heart rhythm ablation with pacemaker-based treatment in adults with atrial fibrillation and heart failure.
Plain-language title generated from the registry record
Registry title: Atrial Fibrillation Ablation Versus Atrioventricular Nodal Ablation with Conduction System Pacing in Heart Failure
Key facts
- Where
- Prague, CzechiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people over 60 with long-lasting atrial fibrillation and heart failure who have symptoms despite medicines and could have an ablation procedure.
- Age
- Over 60 years
- Sex
- All sexes
- Disease stage
- Persistent atrial fibrillation with symptomatic heart failure despite medical therapy. At least one hospital admission, emergency room or heart failure clinic visit for heart failure in the past 2 years, with NT-pro-BNP > 1000 pg/ml or BNP > 250 pg/ml measured in that time.
- Earlier treatment
- Must have had rate or rhythm control drug therapy, now or before. At most one earlier PVI procedure. No pacemaker or CRT device already implanted or planned. An ICD without a pacing need is acceptable.
- Biomarker or test result
- NT-pro-BNP > 1000 pg/ml or BNP > 250 pg/ml measured at any time in the past 2 years.
Main reasons for not taking part
- NYHA Class IV and systolic blood pressure ≤80 mmHg despite optimized therapy
- Life expectancy < 2 years
- Need for major surgery
- Myocardial infarction, stroke or PCI in the past 3 months
- Taking part in another controlled trial
Read by machine on 9 November 2026.
Where in Czechia
- University Hospital Kralovske VinohradyPrague, CzechiaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Geneva
- Trial code
- NCT06207383
- Record updated
- 6 December 2024
- Original description
The goal of this clinical trial is to evaluate two treatment strategies in patients with chronic atrial fibrillation and heart failure, who are eligible for atrial fibrillation ablation. Patients will be randomized to either atrial fibrillation ablation or to implantation of a pacemaker with conduction system pacing followed by atrioventricular node ablation. The effect of treatment allocation on total mortality, cardiovascular hospitalization and heart failure hospitalization will be compared.Read full original descriptionShow less
Catheter ABlation of Atrial Fibrillation Versus Atrioventricular Nodal Ablation with CondUction System Pacing in Persistent Atrial Fibrillation and Heart Failure
The goal of this clinical trial is to evaluate two treatment strategies in patients with chronic atrial fibrillation and heart failure, who are eligible for atrial fibrillation ablation. Patients will be randomized to either atrial fibrillation ablation or to implantation of a pacemaker with conduction system pacing followed by atrioventricular node ablation. The effect of treatment allocation on total mortality, cardiovascular hospitalization and heart failure hospitalization will be compared.
Inclusion: (i) Persistent AF with symptomatic HF despite medical therapy, considered to be suitable for AF ablation, with at most one previous PVI procedure; (ii) At least one prior hospital admission, or emergency room / HF clinic visit for HF in the past 2 years, with NT-pro-BNP > 1000 pg/ml or BNP > 250 pg/ml measured at any timepoint during this interval; (iii) Previous or current rate or rhythm control drug therapy. (iv) Age > 60 years.
Exclusion: (i) NYHA Class IV and systolic blood pressure ≤80 mmHg despite optimized therapy; (ii) Life expectancy < 2 years. (iii) Need for major surgical intervention. (iv) Myocardial infarction, stroke or PCI within the previous 3 months. (v) Previously implanted or planned implantation of CRT device or pacemaker. Implantable cardioverter defibrillator (ICD) implantation without a pacing indication is acceptable; (vi) Participation in another controlled trial. (vii) Inability to sign and informed consent form.